Isolation, characterisation and preliminary cross‐protection studies with a new pathogenic avian infectious bronchitis virus (Strain PL‐84084)

Picault, J. P.; Drouin, P; Guittet, M.; Bennejean, G.; Protais, J.; L'Hospitalier, Rolande; Gillet, J. P.; Lamande, J.; Bachelier, A. Le

doi:10.1080/03079458608436300

Cited by 26 publications

(18 citation statements)

References 7 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In experimental situations this can result in sterile immunity when challenged by virulent homologous virus within three weeks of vaccination. Sometimes, even in closely controlled experimental situations, 10% of vaccinated chicks do not respond with a protective immune response against challenge with the homologous strain [17,29,49,77,82,103]. These results show that chickens (out-bred, though with restricted sets of parental breeding stocks) are not uniform in their response to IBV vaccination.…”

Section: Live Vaccinesmentioning

confidence: 68%

“…First described in the 1930s in the USA, IB research has been dominated by the extensive genetic variation exhibited by the surface spike (S) protein gene, recognised half a century ago as antigenic variation. Specifically, virus neutralisation tests revealed the existence of serotypes (currently numbering dozens), which are poorly cross-protective [9,17,21,29,31,34,36,37,40,49,61,63,82].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Coronavirus avian infectious bronchitis virus

2007

View full text Add to dashboard Cite

-Infectious bronchitis virus (IBV), the coronavirus of the chicken (Gallus gallus), is one of the foremost causes of economic loss within the poultry industry, affecting the performance of both meat-type and egg-laying birds. The virus replicates not only in the epithelium of upper and lower respiratory tract tissues, but also in many tissues along the alimentary tract and elsewhere e.g. kidney, oviduct and testes. It can be detected in both respiratory and faecal material. There is increasing evidence that IBV can infect species of bird other than the chicken. Interestingly breeds of chicken vary with respect to the severity of infection with IBV, which may be related to the immune response. Probably the major reason for the high profile of IBV is the existence of a very large number of serotypes. Both live and inactivated IB vaccines are used extensively, the latter requiring priming by the former. Their effectiveness is diminished by poor cross-protection. The nature of the protective immune response to IBV is poorly understood. What is known is that the surface spike protein, indeed the amino-terminal S1 half, is sufficient to induce good protective immunity. There is increasing evidence that only a few amino acid differences amongst S proteins are sufficient to have a detrimental impact on cross-protection. Experimental vector IB vaccines and genetically manipulated IBVs -with heterologous spike protein genes -have produced promising results, including in the context of in ovo vaccination.

show abstract

Section: Live Vaccinesmentioning

confidence: 68%

Section: Introductionmentioning

confidence: 99%

Coronavirus avian infectious bronchitis virus

2007

View full text Add to dashboard Cite

show abstract

“…In France, the most studied AvCoV has so far been IBV, with outbreaks of infectious bronchitis in the late 1980s leading to the first detection of the CR88 genotype (also named 793/B, or 4/91) (Cavanagh et al, 1998) that replaced the previously prevalent D274 and Massachusetts serotypes (Davelaar et al, 1984;Picault et al, 1986). More recently, two new genotypes, QX and Italy02, have emerged in Europe and in France (Worthington et al, 2008).…”

Section: Discussionmentioning

confidence: 99%

First full-length sequences of the S gene of European isolates reveal further diversity among turkey coronaviruses

et al. 2011

View full text Add to dashboard Cite

An increasing incidence of enteric disorders clinically suggestive of the poult enteritis complex has been observed in turkeys in France since 2003. Using a newly designed real-time reverse transcriptase-polymerase chain reaction assay specific for the nucleocapsid (N) gene of infectious bronchitis virus (IBV) and turkey coronaviruses (TCoV), coronaviruses were identified in 37% of the intestinal samples collected from diseased turkey flocks. The full-length spike (S) gene of these viruses was amplified, cloned and sequenced from three samples. The French S sequences shared 98% identity at both the nucleotide and amino acid levels, whereas they were at most 65% and 60% identical with North American (NA) TCoVand at most 50% and 37% identical with IBV at the nucleotide and amino acid levels, respectively. Higher divergence with NA TCoV was observed in the S1-encoding domain. Phylogenetic analysis based on the S gene revealed that the newly detected viruses form a sublineage genetically related with, but significantly different from, NA TCoV. Additionally, the RNAdependent RNA polymerase gene and the N gene, located on the 5? and 3? sides of the S gene in the coronavirus genome, were partially sequenced. Phylogenetic analysis revealed that both the NA TCoV and French TCoV (Fr TCoV) lineages included some IBV relatives, which were however different in the two lineages. This suggested that different recombination events could have played a role in the evolution of the NA and Fr TCoV. The present results provide the first S sequence for a European TCoV. They reveal extensive genetic variation in TCoV and suggest different evolutionary pathways in North America and Europe.

show abstract

“…In these experiments , groups of 10 chicks were given H120 vaccine at 1 day old, then either revaccinate d at 2 weeks with Ma5 vaccine (of the same serotype), or with the antigenically different 4/91, or not revaccinate d (Figure 1). At approximatel y 5 weeks of age, they were challenged with either the B1648 strain of IBV from Belgium (Meulemans et al, 1987) or recent IBV ® eld isolates from Italy: 710 of the French 84084 serotype (Picault et al, 1986) or 2149 of the French 84221 serotype (Picault et al, 1987).…”

Section: Figure 1 Improved Protection Against Challenge At 5 Weeks Omentioning

confidence: 99%

Breadth of protection of the respiratory tract provided by different live-attenuated infectious bronchitis vaccines against challenge with infectious bronchitis viruses of heterologous serotypes

Cook¹,

Orbell²,

Woods³

et al. 1999

Avian Pathology

220

213

View full text Add to dashboard Cite

The regime of administering the infectious bronchitis (IB) Ma5 vaccine (Massachusetts serotype) at 1 day old and the heterologous 4/91 vaccine at 2 weeks of age, was shown to be highly effective in protecting the respiratory tract of speci® ed pathogen free chickens. Protection, as measured by assessing ciliary activity of the tracheal epithelium following challenge, was excellent against challenge at 5 weeks of age with IB strains of many serotypes, isolated from disease outbreaks in different parts of the world. This vaccination protocol was more effective than revaccination with a vaccine of the same serotype as the ® rst vaccine. Furthermore, signi® cantly better protection was seen when the Ma5 vaccine was given before, rather than at the same time as or following, the 4/91 vaccine.It is suggested that the use of these two IB vaccines will frequently broaden the protection possible against challenge with IB isolates of many different serotypes, without the need to develop a new IB vaccine to combat each new IB serotype that emerges.

show abstract

Isolation, characterisation and preliminary cross‐protection studies with a new pathogenic avian infectious bronchitis virus (Strain PL‐84084)

Cited by 26 publications

References 7 publications

Coronavirus avian infectious bronchitis virus

Coronavirus avian infectious bronchitis virus

First full-length sequences of the S gene of European isolates reveal further diversity among turkey coronaviruses

Breadth of protection of the respiratory tract provided by different live-attenuated infectious bronchitis vaccines against challenge with infectious bronchitis viruses of heterologous serotypes

Contact Info

Product

Resources

About